Table II. Pathway enrichment analysis with proteins upregulated in ERU.
| p value | q-value | Pathway name | Source | Size | Overlap upregulated in ERU1 | Overlap unchanged2 or downregulated3§ |
|---|---|---|---|---|---|---|
| 0.000 | 0.000 | B cell survival pathway | BioCarta | 18 | ITGA1*; ITGB1 | |
| 0.000 | 0.000 | Antigen processing and presentation | BioCarta | 14 | B2M*; HLA-A; TAP1; TAP2 | |
| 0.000 | 0.000 | IL2 | NetPath | 65 | ICAM1; STAT1 | |
| 0.000 | 0.000 | Erk and pi-3 kinase are necessary for collagen binding in corneal epithelia | BioCarta | 34 | ACTA1*; ACTN1*; ACTN4; GSN; ITGA1*; ITGB1; PFN1* | |
| 0.000 | 0.000 | ABC-family proteins mediated transport | Reactome | 4 | ABCD3*; APOA1 | |
| 0.000 | 0.000 | Extrinsic prothrombin activation pathway | BioCarta | 18 | F3*; FGA; FGB; FGG | |
| 0.000 | 0.000 | HDL-mediated lipid transport | Reactome | 11 | ALB; APOA1 | |
| 0.000 | 0.000 | TNF receptor signaling pathway | PID | 47 | CAV1; STAT1 | |
| 0.000 | 0.000 | Primary immunodeficiency | KEGG | 35 | TAP1; TAP2 | |
| 0.000 | 0.000 | Autoimmune thyroid disease (contains “Allograft rejection”; “Graft-versus-host disease”) | KEGG | 52 | HLA-A; HLA-C | |
| 0.000 | 0.000 | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | Reactome | 152 | B2M*; CXADR; HLA-A; HLA-C; ICAM1; ITGB1 | C3; CD81 |
| 0.000 | 0.002 | Integrin cell surface interactions (includes “Integrin alphaIIbbeta3 signaling”; “Grb2:SOS provides linkage to MAPK signaling for Intergrins”) | Reactome | 81 | FGA; FGB; FGG; FN1; ICAM1; ITGA1*; ITGAD*; ITGAV; ITGB1; ITGB8*; LAMB2; LAMC1; VTN* | RAP1B; BSG; COL4A5*; ITGAD*; LAMA5; CO2A1 |
| 0.000 | 0.003 | Integrin signaling pathway | BioCarta | 36 | ACTA1*; ACTN1*; ACTN4; CAV1; ITGA1*; ITGB1 | HRAS* |
| 0.003 | 0.024 | Formation of Fibrin Clot (Clotting Cascade) | Reactome | 33 | F3*; FGA; FGB; FGG | C1QBP |
| 0.003 | 0.023 | Lipoprotein metabolism | Reactome | 27 | ALB; APOA1; HSPG2; P4HB | SAR1B§* |
| 0.003 | 0.022 | Complement and coagulation cascades | KEGG | 69 | F3*; FGA; FGB; FGG | C3 |
| 0.005 | 0.030 | ECM-receptor interaction | KEGG | 84 | CD44; COL6A1*; FN1; HSPG2; ITGA1*; ITGAV; ITGB1; ITGB8*; LAMB2; LAMC1; VTN* | CD47*; CO2A1; DAG1*; ITGAD*; LAMA5; SV2A; SV2B§; TNXB |
| 0.005 | 0.033 | Ucalpain and friends in cell spread | BioCarta | 26 | ACTA1*; ACTN1*; ACTN4; ITGA1*; ITGB1 | RAC1; SPTAN1 |
| 0.010 | 0.059 | Formation of Platelet plug (includes “Platelet activation”, “Platelet Aggregation (Plug Formation)”, “p130Cas linkage to MAPK signaling for integrins”,; “Response to elevated platelet cytosolic Ca2+”, “Platelet degranulation” and “Exocytosis of Alpha granule”) | Reactome | 135 | ACTN1*; ACTN4; ALB; ALDOA; CD9; CLU; FGA; FGB; FGG; FN1; GNG2*; ITGB1; LAMP2* | GNB1; GNB2; GNB3; GNB4*; GNG7; GNG12*; GNAQ; GNA13; ITGAD*; RAP1B; GNG4§*; GNG10§* |
| 0.010 | 0.057 | Focal adhesion | KEGG | 202 | ACTN1*; ACTN4; CAV1; COL6A1*; FLNA; FN1; ITGA1*; ITGAV; ITGB1; ITGB8*; LAMB2; LAMC1; VTN* | ACTB; CDC42; COL2A1; CTNNB1; HRAS; ITGAD*; LAMA5; MYLK2*; PPP1CA*; RAC1; RAP1B; TNXB |
1 p < 0.05 and more than 2 fold upregulated.
2 p > 0.05 or less than 2 fold upregulated.
3 p < 0.05 and more than 0.5 fold downregulated in ERU.
* Identified and quantified by only one peptide.